Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan (Part 1 & Part 2) to the European Medicines Agency (EMA) to evaluate the efficacy and safety of CT-P51 compared with Keytruda in patients with non-small cell lung cancer.
📊 [Key Disclosure Details & Financial Highlights]
- Overview
- Title: Application for Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Europe (Part 1 & 2)
- Application Date: August 22, 2024 (Local Time)
- Regulatory Authority: European Medicines Agency (EMA)
- Board Resolution or Fact Confirmation Date: August 22, 2024
- Clinical Trial Details
- Trial Phase: Global Phase 3 Clinical Trial
- Indication: Non-Small Cell Lung Cancer (NSCLC)
- Clinical Trial Registration Number: EU CT number 2024-514048-98-00
- Objective: To compare efficacy and safety between CT-P51 and Keytruda
- Number of Subjects: 606 patients in total
- Trial Duration: Treatment period of 2 years
- Study Design: Double-blind, randomized, active-controlled, Phase 3 clinical trial
- Future Plans & Important Regulatory Information
- Celltrion aims to demonstrate biosimilarity to the reference drug Keytruda through this Phase 3 trial and expand authorization across all approved indications of the original drug.
- Under revised EU Clinical Trials Regulations, procedures are split into Part 1 (assessment of trial design and methodology) and Part 2 (assessment of trial sites and execution). This disclosure corresponds to the simultaneous submission of both Part 1 and Part 2; final approval up through Part 2 is required to initiate trial execution.
- Statistically, the probability of a clinical-stage drug candidate receiving final market authorization is known to be around 10%, and commercialization plans may be modified or abandoned depending on trial outcomes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Approval Status for Part 1 and Part 2 by the European Medicines Agency (EMA)
This disclosure reports the initial application stage for global Phase 3 clinical trial approval in Europe for CT-P51 (Keytruda biosimilar). Tracking whether final approvals for both Part 1 and Part 2 are granted by regulatory authorities to initiate actual patient dosing and trial execution is important for monitoring the development progress of the company’s pipeline. Detailed updates can be verified in subsequent regulatory disclosures and upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
